NATIVIS, INC. Patent applications |
Patent application number | Title | Published |
20130165734 | TIME-DOMAIN TRANSDUCTION SIGNALS AND METHODS OF THEIR PRODUCTION AND USE - A storage medium having a low frequency time-domain signal stored thereon, and methods of generating, scoring, testing and using the signals are disclosed. In one general embodiment, the signal is derived from a taxane-like compound or an siRNA against human GADPH, and is useful in treating cancer in a subject by exposing the subject a low-magnetic field transduction of the signal. Also disclosed are improved signal transduction methods. | 06-27-2013 |
20130041201 | System and Method for Collecting, Storing, Processing, Transmitting and Presenting Very Low Amplitude Signals - A method and apparatus for producing an effect of a chemical or biochemical agent on a system responsive to such agent, are disclosed. In practicing the method, a plurality of low-frequency time-domain signals of the agent are generated, each at a different at a different noise level within a selected noise level range. The signals are analyzed by producing spectral plots of the time-domain signals, and identifying an optimized agent-specific time-domain signal based on information in the spectral plots. A chemical or biological system responsive to the agent is exposed to the optimized time-domain signal by placing the system within the magnetic field of an electromagnetic transducer, and applying the signal to the transducer at a signal amplitude and for a period sufficient to produce in the system an agent-specific effect on the system. | 02-14-2013 |
20110195111 | AQUEOUS COMPOSITIONS AND METHODS - A method of forming an aqueous composition effective to produce an agent-specific effect on an agent-responsive chemical or biological system, when the composition is added to the system, is disclosed. The composition is formed by exposing an aqueous medium to a low-frequency, time-domain signal derived from the agent, until the aqueous medium acquires a detectable agent activity. Exemplary compositions are formed by exposure to a paclitaxel signal or a signal derived from a therapeutic oligonucleotide, such as GAPDH antisense RNA and PCSK9 antisense RNA. Also disclosed are methods for confirming the activity of the composition, and for preparing and testing the activity of the compositions. | 08-11-2011 |